Summary
75 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 14 JPY is left as net profit.
- Revenue grew by 14% a year over the last 3 years.
What to watch
- It cut its dividend by 21% last year.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.3 JPY for 1 JPY of yearly profit. Over the last five years it was 34.8 JPY on average.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 8.6%.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 47 JPY
- Sales and administration 36 JPY
- Taxes and other 3.0 JPY
- Net profit 14 JPY
Net profit, industry median (Medical - Devices) 6.9 JPY
Out of every 100 JPY of revenue, 14 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.58%
- Paid out of profit
- 32%
You receive $0.23 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.